Skip to main content
JAZZ logo

Jazz Pharmaceuticals plc (JAZZ) Stock: Price, Forecast & Analyst Target

Jazz Pharmaceuticals plc (JAZZ) — MoonshotScore 40/100 (Weak band), calculated Nov 18, 2026. Price $247.77 (+2.93%), as of the Nov 18, 2026 trading session; market cap $15.9B.

Educational signal · not a buy or sell recommendation · How to read this

$247.77 +$7.06 (+2.93%) Market Cap $15.9B

Jazz Pharmaceuticals plc · JAZZ · NASDAQ · Healthcare · Biotechnology

Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Jazz Pharmaceuticals is a commercial drugmaker focused on sleep disorders, severe epilepsies and selected cancers. Its revenue base rests chiefly on Xywav and Epidiolex or Epidyolex, with hematology and oncology products providing additional breadth. The durability question is whether rare-sleep growth and newer medicines can reduce product concentration while supporting a debt load that remains above cash.

Price as of Nov 18, 2026

Key Statistics

40 of 100

MoonshotScore v2 · Jazz Pharmaceuticals (JAZZ)

Weak
Business Quality Elite (86)
Financial Safety Okay (41)
Valuation Fair (63)
Growth Durability Growing (78)
Momentum Surging (81)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.

  • EPS beat 5 of the last 8 reports
  • Altman Z 1.96 · Piotroski F 7
  • ROE 4.6% · ROA 1.7% · current ratio 1.82 · earnings yield 1.3% · free-cash-flow yield 10.2%

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for JAZZ (52 recorded, newest six shown)
RecordedScoreBand
39Weak
39Weak
38Weak
38Weak
40Weak
40Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$247.77
Change on the day+2.93%
52-week range$156.95–$266.38
Market capitalisation$15.9B—
Price / earnings (trailing)67.24
Shares traded on the day721.5K
Beta (volatility vs the S&P 500)0.32

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $131, high $257, latest $248. $257 $131 high $257 Oct 17, 2025 Nov 18, 2026 · $248 $136Oct 17, 2025$138Oct 31, 2025$141Nov 14, 2025$177Nov 28, 2025$168Dec 12, 2025$170Dec 26, 2025$161Jan 9, 2026$169Jan 23, 2026$166Feb 6, 2026$172Feb 20, 2026$182Mar 6, 2026$181Mar 20, 2026$187Apr 2, 2026$203Apr 17, 2026$203May 1, 2026$229May 15, 2026$236May 29, 2026$231Jun 12, 2026$230Jun 26, 2026$244Jul 10, 2026$254Jul 24, 2026$257Aug 7, 2026$254Aug 21, 2026$247Sep 4, 2026$241Sep 18, 2026$236Oct 2, 2026$210Oct 16, 2026$216Oct 30, 2026$242Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Jazz Pharmaceuticals (JAZZ): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Moderate
Growth Durability Moderate
Momentum Strong

Legends Council

3 lenses, 3 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Revenue Growth Neutral
Debt/Equity Negative
ROE Neutral
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Jazz Pharmaceuticals (JAZZ), and what does it report?

Short answer · as of

Jazz sells prescription medicines to narrowly defined patient populations rather than relying on a discovery platform without commercial products.

Reported revenue largely measures sales of named therapies, supplemented by a separately disclosed oxybate royalty stream, while the development portfolio represents potential future indications and products.

Xywav is the largest disclosed revenue source, followed by Epidiolex or Epidyolex, while Rylaze or Enrylaze and Zepzelca add hematology and oncology exposure. The pipeline extends into additional solid tumors, blood cancers, glioma and epilepsy, so research spending supports a broader set of opportunities than the current revenue mix suggests.

2 · Latest results

What do the latest results show for Jazz Pharmaceuticals (JAZZ)?

Revenue rose from the preceding period and reached the upper end of the disclosed quarterly run. Operating profit also increased, but net income and diluted earnings declined as research spending climbed materially.

Revenue exceeded expectations at the latest release while earnings fell short, a different pattern from the preceding release when each surpassed expectations. Management continues to expect Xywav growth and has issued a rare-sleep revenue outlook, but product sales must still substantiate that guidance.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2026$1.24B-$483M-$7.47 (diluted)
Q2 FY2026$1.21B$193M$2.78 (diluted)
Q1 FY2026$1.07B$293M$4.43 (diluted)
Q4 FY2025$1.20B$203M$3.34 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Jazz Pharmaceuticals (JAZZ)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Established products generate substantial cash: operating cash flow has remained positive throughout the disclosed quarterly series, while capital spending has generally been modest beside that inflow. Trailing margins and free-cash-flow yield likewise reflect a profitable commercial portfolio, even though annual net results have moved between profit and loss.

Jazz is not a net-cash business. Debt exceeds cash and investments, and liquidity ended below its level at the start of the reported window despite continued operating inflows. A setback in Xywav demand or sustained spending on programs that fail to become meaningful products would therefore compete with debt reduction and future reinvestment.

4 · What to check next?

What should you watch next at Jazz Pharmaceuticals (JAZZ)?

Short answer · as of

Current published price targets run low $220.00 · high $337.00 · consensus $295.73 · median $300.00 against a quoted price of $247.77 (as of Nov 18, 2026).

At the scheduled earnings update, track Xywav against management’s rare-sleep outlook, then examine whether Epidiolex or Epidyolex, Rylaze or Enrylaze and Zepzelca are making the revenue mix less dependent on the sleep franchise. The recent revenue beat sets a demanding comparison, while the accompanying earnings miss makes expense discipline equally important.

Revenue growth alone will not settle the issue. Operating profit, research spending, cash conversion and the movement of cash relative to debt will show whether commercial momentum is strengthening financial flexibility. Consensus estimates assume continued revenue and earnings expansion across the forecast horizon, leaving product-level execution as the evidence that matters.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Jazz Pharmaceuticals compare with its peers?

Short answer

Jazz Pharmaceuticals's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Jazz occupies a middle ground between mature specialty pharmaceutical companies and development-focused biotechnology businesses. It already has profitable, cash-generating franchises that can finance a wide clinical slate, yet its economics remain more concentrated in named therapies than those of a broadly diversified drugmaker.

A distinctive feature is the pairing of direct Xywav sales with a separate royalty stream from a high-sodium authorized generic oxybate product. Epidiolex or Epidyolex adds severe-epilepsy exposure, while Rylaze or Enrylaze and Zepzelca bring different cancer settings; comparisons therefore depend more on indication-specific commercial execution than on pipeline size alone.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Exelixis, Inc. (EXEL) Same industry, near in market value$68.29 Nov 18, 2026$16.7B98 5-pillar Nov 18, 2026
United Therapeutics Corporation (UTHR) Same industry, near in market value$577.34 Nov 18, 2026$24.6B97 5-pillar Nov 18, 2026
Ascendis Pharma A/S (ASND) Same industry, near in market value$270.33 Nov 18, 2026$17.7B96 5-pillar Nov 18, 2026
Krystal Biotech, Inc. (KRYS) Same industry, near in market value$315.34 Nov 18, 2026$9.34B96 5-pillar Nov 18, 2026
Neurocrine Biosciences, Inc. (NBIX) Same industry, near in market value$162.86 Nov 18, 2026$16.5B95 5-pillar Nov 18, 2026
Halozyme Therapeutics, Inc. (HALO) Same industry, near in market value$95.80 Nov 18, 2026$10.9B95 5-pillar Nov 18, 2026
Bio-Techne Corporation (TECH) Same industry, near in market value$72.75 Nov 18, 2026$11.4B92 5-pillar Nov 18, 2026
Incyte Corporation (INCY) Same industry, near in market value$117.80 Nov 18, 2026$24.0B91 5-pillar Nov 18, 2026
TG Therapeutics, Inc. (TGTX) Same industry, near in market value$66.12 Nov 18, 2026$9.99B90 5-pillar Nov 18, 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Same industry, near in market value$149.40 Nov 18, 2026$20.0B72 5-pillar Nov 18, 2026
Abivax S.A. (ABVX) Named competitor$83.83 Nov 18, 2026$7.34B53 5-pillar Nov 18, 2026
Jazz Pharmaceuticals (JAZZ) — this page$247.77$15.9B40
Madrigal Pharmaceuticals, Inc. (MDGL) Named competitor$398.08 Nov 18, 2026$9.25B35 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$220.00 – $337.00
Consensus target
$295.73
Median target
$300.00

Consensus record · Captured .

Measured against a quoted price of $247.77 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026

Transactions
86
Identified insiders
18
Purchases
0
Sales
25
Other transactions
61

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held JAZZ in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.15%$33.61MNew position

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Jazz Pharmaceuticals (JAZZ)?

Read these with our analysis →

What Investors Ask About Jazz Pharmaceuticals (JAZZ) — Healthcare

The last 2 questions are answered from this page's own dated data, not from the research.

Why is Xywav so important to Jazz Pharmaceuticals?

Xywav is Jazz’s largest disclosed revenue stream and anchors management’s rare-sleep outlook. Its growth affects portfolio expansion, cash generation and the company’s capacity to support development spending while carrying net debt.

How does Epidiolex or Epidyolex diversify Jazz?

Epidiolex or Epidyolex sits behind only Xywav among the disclosed revenue streams and serves severe seizure disorders rather than sleep medicine. It gives Jazz a sizable commercial franchise whose demand is tied to different diseases and patients.

What is unusual about Jazz’s oxybate revenue model?

Jazz reports direct Xywav product revenue alongside a separate royalty from a high-sodium authorized generic oxybate product. The company therefore participates in oxybate economics through distinct revenue channels.

Can Jazz’s oncology products offset its sleep concentration?

Rylaze or Enrylaze and Zepzelca already contribute meaningful sales, and newer cancer medicines broaden the commercial and development slate. Their disclosed combined contribution remains below Xywav, so oncology diversification is underway rather than complete.

What is the JAZZ stock price today?

The last price recorded for Jazz Pharmaceuticals plc (JAZZ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the JAZZ price target?

The analyst consensus price target for Jazz Pharmaceuticals plc (JAZZ), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-13), by section of the research

  • Summary at the top of the page: Legal name; Business description; Revenue by segment; Cash, investments and debt; Management outlook — dated call excerpts
  • 1. What is Jazz Pharmaceuticals (JAZZ), and what does it report?: Business description; Revenue by segment; Quarterly income statement (USD thousands); Annual revenue and net result (USD millions)
  • 2. What do the latest results show for Jazz Pharmaceuticals (JAZZ)?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts; Most recent periodic reports
  • 3. What are the financial strengths and risks for Jazz Pharmaceuticals (JAZZ)?: Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set; Annual revenue and net result (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash decline over the reported window; Cash against market value; Revenue by segment
  • 4. What should you watch next at Jazz Pharmaceuticals (JAZZ)?: Next earnings report; Management outlook — dated call excerpts; Reported versus estimated, last 8 quarters; Analyst revenue and earnings estimates (average); Revenue by segment; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash and short-term investments over time (USD millions); Cash, investments and debt
  • 5. How does Jazz Pharmaceuticals compare with its peers?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Operating cash flow by quarter (USD millions); Trailing twelve-month ratio set
  • FAQ: Why is Xywav so important to Jazz Pharmaceuticals?: Revenue by segment; Management outlook — dated call excerpts; Quarterly income statement (USD thousands); Cash, investments and debt
  • FAQ: How does Epidiolex or Epidyolex diversify Jazz?: Business description; Revenue by segment
  • FAQ: What is unusual about Jazz’s oxybate revenue model?: Revenue by segment; Business description
  • FAQ: Can Jazz’s oncology products offset its sleep concentration?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold JAZZ

Funds in our ETF coverage that list JAZZ among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
Simplify Health Care ETF (PINK)3.92%
iShares Focused Value Factor ETF (FOVL)2.68%
Alger Russell Innovation ETF (INVN)2.52%